A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Xu Zhang) · xzhang@foxmail.com · +86-010-66937166
Contact: Principal Investigator (Xu Zhang)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostatic Neoplasms · Metastatic Hormone-Sensitive Prostate Cancer

Abroad (travel likely)Recruiting

Cleveland, United States

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-sensitive Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States · Santa Monica, United States

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Abroad (travel likely)RecruitingPHASE3

Aalst, Belgium · Antwerp, Belgium

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Abroad (travel likely)RecruitingPHASE3

Nanjing, China